On May 18, 2026, Board of Directors member Dr.
Carladenise Armbrister Edwards reported a direct sale of 67,160 shares of Clover Health Investments (NASDAQ:CLOV) in an open-market transaction, according to the SEC Form 4 filing
Transaction summary Transaction value based on SEC Form 4 weighted average reported price ($3.42); post-transaction value based on May 18, 2026 closing price. Key questions – How does this transaction compare to Edwards’ historical trading activity? This is Edwards’ second direct sale in the past two years, with the previous transaction in March 2025 involving 200,000 shares; the latest sale of 67,160 shares is smaller in scale, reflecting reduced available holdings. – What portion of Edwards’ position was affected by this sale?
The transaction reduced Edwards’ direct holdings by 19.05%, from 352,592 to 285,432 shares. – Was this sale influenced by recent market performance or valuation? The sale price of around $3.42 per share was modestly below the market close price during a period when the stock’s one-year total return was 8.23%, indicating the transaction occurred amid muted performance and may reflect routine portfolio management. – What is the remaining ownership profile for Edwards after the transaction? Following this sale, Edwards continues to hold 285,432 shares of Common Stock directly, with no indirect or derivative securities reported, representing a continuing material stake in Clover Health Investments.